These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 34958004)

  • 1. Evaluation of CDCP1 (CD318) and endoglin (CD105) expression as prognostic markers in acute myeloid leukemia.
    Ebian HF; Issa DR; Al-Karamany AS; Etewa RL; El Maghraby HM; Hussein S
    Cancer Biomark; 2022; 34(2):285-296. PubMed ID: 34958004
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of CD318 (CDCP1) as novel prognostic marker in AML.
    Heitmann JS; Hagelstein I; Hinterleitner C; Roerden M; Jung G; Salih HR; Märklin M; Kauer J
    Ann Hematol; 2020 Mar; 99(3):477-486. PubMed ID: 31965270
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD105 (endoglin) as risk marker in AML patients undergoing stem cell transplantation.
    Märklin M; Hagelstein I; Hinterleitner C; Salih HR; Kauer J; Heitmann JS
    Int J Hematol; 2020 Jul; 112(1):57-64. PubMed ID: 32266669
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD105 (Endoglin) as negative prognostic factor in AML.
    Kauer J; Schwartz K; Tandler C; Hinterleitner C; Roerden M; Jung G; Salih HR; Heitmann JS; Märklin M
    Sci Rep; 2019 Dec; 9(1):18337. PubMed ID: 31797971
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD105 (endoglin) is highly overexpressed in a subset of cases of acute myeloid leukemias.
    Chakhachiro ZI; Zuo Z; Aladily TN; Kantarjian HM; Cortes JE; Alayed K; Nguyen MH; Medeiros LJ; Bueso-Ramos C
    Am J Clin Pathol; 2013 Sep; 140(3):370-8. PubMed ID: 23955456
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of FLT3-Activating Mutations in Patients With Acute Myelogenous Leukemia in Jordan: Association With FAB Subtypes and Identification of Subgroups With Poor Prognosis.
    Halahleh K; Taqash A; Abdelkhaleq H; Manasrah M; Marie L; Al-Rabi K
    Clin Lymphoma Myeloma Leuk; 2021 Jul; 21(7):e588-e597. PubMed ID: 33811005
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and hematological correlates of aberrant immunophenotypic profiles in adult and pediatric acute myeloid leukemia at presentation.
    Sharma M; Varma N; Singh Sachdeva MU; Bose P; Varma S
    J Cancer Res Ther; 2020; 16(1):105-109. PubMed ID: 32362618
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High bone marrow miR-19b level predicts poor prognosis and disease recurrence in de novo acute myeloid leukemia.
    Zhang TJ; Lin J; Zhou JD; Li XX; Zhang W; Guo H; Xu ZJ; Yan Y; Ma JC; Qian J
    Gene; 2018 Jan; 640():79-85. PubMed ID: 29032147
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical, molecular, and prognostic significance of WHO type inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and various other 3q abnormalities in acute myeloid leukemia.
    Lugthart S; Gröschel S; Beverloo HB; Kayser S; Valk PJ; van Zelderen-Bhola SL; Jan Ossenkoppele G; Vellenga E; van den Berg-de Ruiter E; Schanz U; Verhoef G; Vandenberghe P; Ferrant A; Köhne CH; Pfreundschuh M; Horst HA; Koller E; von Lilienfeld-Toal M; Bentz M; Ganser A; Schlegelberger B; Jotterand M; Krauter J; Pabst T; Theobald M; Schlenk RF; Delwel R; Döhner K; Löwenberg B; Döhner H
    J Clin Oncol; 2010 Aug; 28(24):3890-8. PubMed ID: 20660833
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Up-regulation of regulatory T cells, CD200 and TIM3 expression in cytogenetically normal acute myeloid leukemia.
    Zahran AM; Mohammed Saleh MF; Sayed MM; Rayan A; Ali AM; Hetta HF
    Cancer Biomark; 2018; 22(3):587-595. PubMed ID: 29843224
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BCL3 Expression Is a Potential Prognostic and Predictive Biomarker in Acute Myeloid Leukemia of FAB Subtype M2.
    Niu Y; Yang X; Chen Y; Zhang L; Jin X; Tang Y; Li L; Yu L; Guo Y; Wang H
    Pathol Oncol Res; 2019 Apr; 25(2):541-548. PubMed ID: 30357752
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic significance of CEBPA mutations and BAALC expression in acute myeloid leukemia Egyptian patients with normal karyotype.
    El-Sharnouby JA; Ahmed LM; Taha AM; Kamal O
    Egypt J Immunol; 2008; 15(1):131-43. PubMed ID: 20306678
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical implications and genetical insights of SOX6 expression in acute myeloid leukemia.
    Li Y; Jiang D; Zhang Q; Liu E; Shao H
    J Cancer Res Clin Oncol; 2023 Jul; 149(8):4443-4453. PubMed ID: 36117190
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Blast vacuolization in AML patients indicates adverse-risk AML and is associated with impaired survival after intensive induction chemotherapy.
    Ballo O; Stratmann J; Serve H; Steffen B; Finkelmeier F; Brandts C
    PLoS One; 2019; 14(9):e0223013. PubMed ID: 31568521
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical significance of dysregulation of miR-381 in pediatric acute myeloid leukemia.
    Zhang P; Sun D; Sun X; Li H
    Eur J Med Res; 2020 Sep; 25(1):42. PubMed ID: 32938467
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value of bone marrow MUC4 expression in acute myeloid leukaemia.
    Abdelhady AS; Abdel Hamid FF; Hassan NM; Ibrahim DM
    Br J Biomed Sci; 2020 Oct; 77(4):202-207. PubMed ID: 32270747
    [No Abstract]   [Full Text] [Related]  

  • 17. Measurable residual disease monitoring using Wilms tumor gene 1 expression in childhood acute myeloid leukemia based on child-specific reference values.
    Løvvik Juul-Dam K; Guldborg Nyvold C; Vålerhaugen H; Zeller B; Lausen B; Hasle H; Beier Ommen H
    Pediatr Blood Cancer; 2019 Jun; 66(6):e27671. PubMed ID: 30900388
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of CD105 (endoglin) as novel risk marker in CLL.
    Greiner SM; Märklin M; Holzmayer S; Kaban K; Meyer S; Hinterleitner C; Tandler C; Hagelstein I; Jung G; Salih HR; Heitmann JS; Kauer J
    Ann Hematol; 2022 Apr; 101(4):773-780. PubMed ID: 35044512
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype.
    Bloomfield CD; Lawrence D; Byrd JC; Carroll A; Pettenati MJ; Tantravahi R; Patil SR; Davey FR; Berg DT; Schiffer CA; Arthur DC; Mayer RJ
    Cancer Res; 1998 Sep; 58(18):4173-9. PubMed ID: 9751631
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CDCP1 identifies a broad spectrum of normal and malignant stem/progenitor cell subsets of hematopoietic and nonhematopoietic origin.
    Bühring HJ; Kuçi S; Conze T; Rathke G; Bartolović K; Grünebach F; Scherl-Mostageer M; Brümmendorf TH; Schweifer N; Lammers R
    Stem Cells; 2004; 22(3):334-43. PubMed ID: 15153610
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.